Minimally Important Difference of Health Assessment Questionnaire in Psoriatic Arthritis: Relating Thresholds of Improvement in Functional Ability to Patient-rated Importance and Satisfaction

REFERENCES

1. 1.↵
   1. Ritchlin CT,
   2. Kavanaugh A,
   3. Gladman DD,
   4. Mease PJ,
   5. Helliwell P,
   6. Boehncke WH,
   7. et al.

   Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387–94.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Gottlieb A,
   2. Korman NJ,
   3. Gordon KB,
   4. Feldman SR,
   5. Lebwohl M,
   6. Koo JY,
   7. et al.

   Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851–64.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Gladman DD,
   2. Landewe R,
   3. McHugh NJ,
   4. Fitzgerald O,
   5. Thaci D,
   6. Coates L,
   7. et al.

   Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010;37:453–61.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Mease PJ

   . Assessment tools in psoriatic arthritis. J Rheumatol 2008;35:1426–30.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Stanford University Medical Center

   . ARAMIS: HAQ. [Internet. Accessed July 22, 2011.] Available from: http://aramis.stanford.edu/HAQ.html
6. 6.↵
   1. Mease PJ,
   2. Antoni CE,
   3. Gladman DD,
   4. Taylor WJ

   . Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii49–54.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Beaton DE,
   2. Boers M,
   3. Wells GA

   . Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 2002; 14:109–14.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Beaton DE,
   2. Bombardier C,
   3. Katz JN,
   4. Wright JG,
   5. Wells G,
   6. Boers M,
   7. et al.

   Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal clinically important difference. J Rheumatol 2001;28:400–5.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Mease PJ,
   2. Ganguly R,
   3. Wanke L,
   4. Yu E,
   5. Singh A

   . How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) group guidelines [abstract]. Ann Rheum Dis 2004;63 Suppl 1:SAT0015.

   OpenUrl
10. 10.↵
    1. Mease PJ,
    2. Kivitz AJ,
    3. Burch FX,
    4. Siegel EL,
    5. Cohen SB,
    6. Ory P,
    7. et al.

    Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712–21.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Mease PJ,
    2. Goffe BS,
    3. Metz J,
    4. VanderStoep A,
    5. Finck B,
    6. Burge DJ

    . Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385–90.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Mease PJ,
    2. Woolley JM,
    3. Singh A,
    4. Tsuji W,
    5. Dunn M,
    6. Chiou C-F

    . Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 2010;37:1221–7.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Norman GR,
    2. Sloan JA,
    3. Wyrwich KW

    . Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582–92.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Revicki D,
    2. Hays RD,
    3. Cella D,
    4. Sloan J

    . Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102–9.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Wyrwich KW,
    2. Nienaber NA,
    3. Tierney WM,
    4. Wolinsky FD

    . Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37:469–78.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Hays RD,
    2. Woolley JM

    . The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 2000;18:419–23.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Ware JE Jr.,
    2. Bayliss MS,
    3. Rogers WH,
    4. Kosinski M,
    5. Tarlov AR

    . Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems. Results from the Medical Outcomes Study. JAMA 1996; 276:1039–47.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Mease PJ,
    2. Kivitz AJ,
    3. Burch FX,
    4. Siegel EL,
    5. Cohen SB,
    6. Ory P,
    7. et al.

    Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264–72.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Redelmeier DA,
    2. Lorig K

    . Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993;153:1337–42.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Kosinski M,
    2. Zhao SZ,
    3. Dedhiya S,
    4. Osterhaus JT,
    5. Ware JE Jr.

    . Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478–87.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Wells GA,
    2. Tugwell P,
    3. Kraag GR,
    4. Baker PR,
    5. Groh J,
    6. Redelmeier DA

    . Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol 1993;20:557–60.

    OpenUrlPubMed
22. 22.↵
    1. Wheaton L,
    2. Pope J

    . The minimally important difference for patient-reported outcomes in spondyloarthropathies including pain, fatigue, sleep, and Health Assessment Questionnaire. J Rheumatol 2010;37:816–22.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Kwok T,
    2. Pope JE

    . Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol 2010;37:1024–8.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Wolfe F,
    2. Michaud K,
    3. Strand V

    . Expanding the definition of clinical differences: From minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 2005;32:583–9.

    OpenUrlAbstract/FREE Full Text